{"id":892297,"date":"2025-10-03T10:53:22","date_gmt":"2025-10-03T14:53:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marking-eczema-awareness-month-clinical-research-validates-strata-skin-sciences-xtrac-excimer-laser-as-a-breakthrough-therapy-for-localized-atopic-dermatitis\/"},"modified":"2025-10-03T10:53:22","modified_gmt":"2025-10-03T14:53:22","slug":"marking-eczema-awareness-month-clinical-research-validates-strata-skin-sciences-xtrac-excimer-laser-as-a-breakthrough-therapy-for-localized-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marking-eczema-awareness-month-clinical-research-validates-strata-skin-sciences-xtrac-excimer-laser-as-a-breakthrough-therapy-for-localized-atopic-dermatitis\/","title":{"rendered":"Marking Eczema Awareness Month \u2013 Clinical Research Validates Strata Skin Sciences\u2019 XTRAC\u00ae Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis"},"content":{"rendered":"
\n

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) — In recognition of Eczema Awareness Month<\/em>, STRATA Skin Sciences, Inc. (\u201cSTRATA\u201d or the \u201cCompany\u201d) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC\u00ae<\/sup> Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common form of eczema. This recognition comes as the American Medical Association (AMA) has expanded excimer laser\u2019s indications to inflammatory and autoimmune skin diseases, clearing the way for Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment.<\/p>\n

Dr. Dolev Rafeli, Strata\u2019s CEO, stated, \u201cExcimer laser treatment continues to capture market share among dermatologists because it remains effective, safe and durable. Despite the fact that this treatment has been around more than 20 years, providers, advocacy groups, academic key opinion leaders and others have advocated for it to be reimbursed across an expanded array of skin conditions, which are now being implemented across the different managed care platforms both public and private. Further, it continues to capture interest among healthcare providers who conduct independent studies that have resulted in hundreds of publications since its original approval and continue today. We continue to collaborate with these providers to optimize treatment for those patients experiencing these otherwise difficult to manage skin conditions.\u201d<\/p>\n

\n Addressing an Urgent Need<\/strong>\n <\/p>\n

Atopic dermatitis affects more than 9.6 million children and 16.5 million adults in the United States. Beyond visible symptoms such as pain, fissures, and intense itching, the condition severely impacts daily living, sleep, work productivity, and emotional well-being. Despite its prevalence, many patients struggle with limited or ineffective treatment options.<\/p>\n

\u201cThe excimer laser is one of our most effective treatments for localized eczema,\u201d said Dr. Mark G. Lebwohl, M.D., Dean for Clinical Therapeutics, Professor and Chairman Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai a global leader in dermatology and phototherapy research.<\/p>\n

\n Robust Clinical Evidence<\/strong>\n <\/p>\n